Patent intelligence · US
US 10610563
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
Patent details — US 10610563
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 7, 2020
- Expiration
- Apr 2, 2040
- Applicant
- BIOXCEL CORPORATION
- Claims
- 25
- CPC classes
- A61K, A61K31/39, A61K31/573, A61K31/69
Quick answer
US 10610563 (Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2) is held by BIOXCEL CORPORATION. Status: granted. Granted Apr 7, 2020. Expires Apr 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOXCEL CORPORATION
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/39, A61K31/573, A61K31/69, A61K38/05, A61K38/07
More from BIOXCEL CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12364683
Non-sedating dexmedetomidine treatment regimens
granted -
US 12138247
Non-sedating dexmedetomidine treatment regimens
granted -
US 12109196
Non-sedating dexmedetomidine treatment regimens
granted -
US 12090140
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998528
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998529
Non-sedating dexmedetomidine treatment regimens
granted -
US 11931340
Use of sublingual dexmedetomidine for the treatment of agitation
granted -
US 11890272
Non-sedating dexmedetomidine treatment regimens
granted
Frequently asked questions
What is US patent 10610563?
US 10610563 (Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2) is held by BIOXCEL CORPORATION. Status: granted. Granted Apr 7, 2020. Expires Apr 2, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10610563?
BIOXCEL CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 10610563 expire?
Our index shows an expiration date of Apr 2, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.